Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 894 posts found.

donald_trump_29496131773

Donald Trump thanks Novartis for halting price hikes

July 20, 2018
Medical Communications Novartis, Pfizer, Trump, Twitter, price hikes

Donald Trump has thanked Swiss multinational Novartis for halting price hikes on prescription drugs in the United States. The US …

News
shutterstock_138095450

Novartis follows Pfizer’s lead, pledges no price hikes in 2018

July 18, 2018
Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma

Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …

News

FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer

July 16, 2018
Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Pfizer, Sanofi, Trump, top 10

In the week leading up to Donald Trump’s visit to the United Kingdom, the news has been dominated by the …

News

Pfizer restructures in preparation for potential sell off

July 12, 2018
Sales and Marketing Pfizer, bisoimilar, consumer, health

Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from …

News
shutterstock_254160583

Trump forces Pfizer to back down and delay price hikes until 2019

July 11, 2018
Research and Development, Sales and Marketing Alex Azar, Donald Trump, Ian Read, Pfizer, President trump, Trump, druig pricing, pharma

Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the …

News
mario_saltarelli_cropped

Syntimmune appoints Pfizer, AbbVie veteran as new CMO

July 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune

The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …

Appointment
donald_trump_september_3_2015

Trump slams Pfizer over price hikes, Pfizer responds

July 10, 2018
Manufacturing and Production, Sales and Marketing Donald Trump, Drug pricing, Pfizer, Trump, pharma

Price hiking in the pharmaceutical industry continues to persist, and has become ever more prominent in the public sphere thanks …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Astrazenaca, Donald Trump, Pfizer, pharma, top ten

As the first week of July comes to an end we take a look over the most popular stories of …

News
shutterstock_138095450

Unfazed by Trump, Pfizer hikes prices for 100 of its drugs

July 3, 2018
Manufacturing and Production, Sales and Marketing Pfizer, President trump, Trump, pharma, price hikes

After a campaign full of not-so-veiled threats directed at the pharma industry, and a presidency which has so far failed …

News

Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis

June 29, 2018
Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …

News

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018
Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …

News
pfizerbrussels_web

Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma

Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …

News
pfizer_chrome_plate

Pfizer successfully appeals 2,600% price hiking case

June 8, 2018
Medical Communications Flynn Pharma, Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer and co-defendant Flynn Pharma have won their appeal against a £90 million fine imposed on them by the Competition …

News

Pfizer pumps $600m into venture fund, targeting neuroscience

June 7, 2018
Research and Development, Sales and Marketing Pfizer, biotech, drugs, neuroscience, pharma, pharmaceutical

Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026